Sun Pharma Advanced Research Company share news, announcements and annual reports
NSE: SPARCBSE: 532872Pharmaceuticals & BiotechnologySmall Cap
Sun Pharma Advanced Research Company Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 2007
Last close ₹175.09down ₹1.37 (0.78%)BSE ₹175.10
Share price at the NSE close on 2 Nov 2026. Previous close ₹176.46.
2 Nov: open ₹177.01, high ₹179.05, low ₹173.41
52-week range of traded prices to 2 Nov 2026
₹108.00Low, 23 Mar 2026₹289.00High, 8 Jul 2026
- Next results date: the board meets on 2 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹5,682 Cr778th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 3.47
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.94
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record.
- 113.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 112.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 5,06,78638.4% delivered
Sun Pharma Advanced Research Company shareholder meetings
68 filed, newest first. Page 1 of 2.
Aug 2026
10 Aug · Meeting
Jul 2026
Feb 2026
Jan 2026
Aug 2025
Jul 2025
Aug 2024
Jul 2024
18 Jul · Meeting
Aug 2023
Jul 2023
14 Jul · Meeting
Sep 2022
Aug 2022
Oct 2021
Sep 2021
30 Sep · Meeting
Jun 2021
May 2021
Apr 2021
Oct 2020
Sep 2020
Jul 2019
30 Jul · Meeting
Jul 2018
30 Jul · Meeting
5 Jul · Meeting
Aug 2017
Jul 2017
10 Jul · Meeting
Jun 2017
May 2017
Sep 2016
Aug 2016
17 Aug · Meeting
Jul 2016
Jun 2016
Aug 2015